CureVac NV Ordinary Shares 5CV
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if 5CV is a good fit for your portfolio.
News
Trading Information
- Previous Close Price
- €3.70
- Day Range
- €3.70–3.70
- 52-Week Range
- €2.16–125.44
- Bid/Ask
- €0.00 / €0.00
- Market Cap
- €829.93 Mil
- Volume/Avg
- 0 / 182,052
Key Statistics
- Price/Earnings (Normalized)
- 20.56
- Price/Sales
- 14.05
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
CureVac is a biopharmaceutical company headquartered in Germany that is developing vaccines and therapies using messenger ribonucleic acid (mRNA). The company was founded in 2000 and had its initial public offering in August 2020. CureVac is collaborating with GSK to develop a second-generation covid vaccine. CureVac’s first attempt to develop a covid vaccine did not have sufficient efficacy data, and its trials were discontinued in October 2021. The company’s other pipeline candidates include mRNA vaccines for influenza, rabies, and malaria. Additionally, CureVac is in the early stages of development for oncology and molecular therapies spanning tumors, liver, ocular, and lung diseases.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 1,100
- Website
- https://www.curevac.com
Competitors
Valuation
|
Metric
|
5CV
|
BNTX
|
UTHR
|
|---|---|---|---|
Price/Earnings (Normalized) | 20.56 | 29.04 | 14.68 |
Price/Book Value | 1.86 | 1.02 | 2.39 |
Price/Sales | 14.05 | 7.51 | 5.73 |
Price/Cash Flow | — | — | 12.30 |
Price/Earnings
5CV
BNTX
UTHR
Financial Strength
|
Metric
|
5CV
|
BNTX
|
UTHR
|
|---|---|---|---|
Quick Ratio | 2.04 | 10.95 | 3.50 |
Current Ratio | 2.25 | 11.38 | 3.77 |
Interest Coverage | −152.59 | — | 21.30 |
Quick Ratio
5CV
BNTX
UTHR
Profitability
|
Metric
|
5CV
|
BNTX
|
UTHR
|
|---|---|---|---|
Return on Assets (Normalized) | −27.79% | −0.14% | 16.45% |
Return on Equity (Normalized) | −39.80% | −0.15% | 20.12% |
Return on Invested Capital (Normalized) | −38.92% | −2.21% | 16.17% |
Return on Assets
5CV
BNTX
UTHR
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| Vvsrdpwl | Tnvlng | $124.1 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Lghlldbtr | Bwbhyh | $114.2 Bil | |||
| Moderna Inc
MRNA
| Ltggctycy | Knpz | $53.7 Bil | |||
| argenx SE ADR
ARGX
| Qphmyhxz | Tgz | $23.0 Bil | |||
| BioNTech SE ADR
BNTX
| Wlnkdyc | Tkmlc | $22.2 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Wwpnqmlx | Nzglvc | $20.3 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Bwpqrbcg | Dppts | $15.9 Bil | |||
| United Therapeutics Corp
UTHR
| Mnwpglsm | Krgz | $12.8 Bil | |||
| Incyte Corp
INCY
| Cvdjpfn | Lskzrv | $12.2 Bil | |||
| Royalty Pharma PLC Class A
RPRX
| Jybngrhf | Hkkntpb | $12.2 Bil |